Payment overview · 2025
General Payments
$98.54
5 reported records · 4 companies
Healthcare provider profile · identity verified
Daniela M Donoso Pena, MD
Allopathic & Osteopathic Physicians|Internal Medicine · RED OAK, IA · NPI 1265744916
Verified facts
What the public records show
CMS Open Payments records show Daniela M Donoso Pena, MD received $98.54 in general payments during 2025 across 5 reported records.
Novartis Pharmaceuticals Corporation accounted for 40.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 5 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $40.06 | 40.6% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $24.86 | 25.2% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $18.52 | 18.8% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $15.10 | 15.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $98.54 | 5 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $40.06 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $24.86 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $18.52 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $15.10 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $15.10 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 58 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
58 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 710 | 115 |
| Atorvastatin Calcium | Atorvastatin Calcium | 481 | 103 |
| Potassium Chloride | Potassium Chloride | 393 | 80 |
| Amlodipine Besylate | Amlodipine Besylate | 389 | 74 |
| Losartan Potassium | Losartan Potassium | 378 | 83 |
| Metoprolol Succinate | Metoprolol Succinate | 338 | 68 |
| Pantoprazole Sodium | Pantoprazole Sodium | 332 | 75 |
| Omeprazole | Omeprazole | 323 | 75 |
| Gabapentin | Gabapentin | 274 | 50 |
| Lisinopril | Lisinopril | 274 | 55 |
| Furosemide | Furosemide | 262 | 59 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 253 | 64 |
| Tramadol Hcl | Tramadol Hcl | 246 | 28 |
| Eliquis | Apixaban | 236 | 38 |
| Metoprolol Tartrate | Metoprolol Tartrate | 215 | 35 |
| Meloxicam | Meloxicam | 190 | 45 |
| Simvastatin | Simvastatin | 181 | 49 |
| Hydrochlorothiazide | Hydrochlorothiazide | 155 | 38 |
| Tamsulosin Hcl | Tamsulosin Hcl | 151 | 32 |
| Trazodone Hcl | Trazodone Hcl | 149 | 26 |
| Duloxetine Hcl | Duloxetine Hcl | 144 | 29 |
| Citalopram Hbr | Citalopram Hydrobromide | 139 | 28 |
| Xarelto | Rivaroxaban | 139 | 11 |
| Donepezil Hcl | Donepezil Hcl | 138 | 21 |
| Metformin Hcl Er | Metformin Hcl | 130 | 26 |
| Metformin Hcl | Metformin Hcl | 129 | 28 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 123 | 17 |
| Sertraline Hcl | Sertraline Hcl | 123 | 21 |
| Mounjaro | Tirzepatide | 113 | 21 |
| Montelukast Sodium | Montelukast Sodium | 107 | 17 |
| Buspirone Hcl | Buspirone Hcl | 106 | 19 |
| Warfarin Sodium | Warfarin Sodium | 106 | 19 |
| Alendronate Sodium | Alendronate Sodium | 102 | 26 |
| Myrbetriq | Mirabegron | 101 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 95 | 13 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 94 | 12 |
| Breo Ellipta | Fluticasone/Vilanterol | 91 | 12 |
| Finasteride | Finasteride | 91 | 14 |
| Mirtazapine | Mirtazapine | 88 | 13 |
| Prednisone | Prednisone | 86 | 39 |
| Escitalopram Oxalate | Escitalopram Oxalate | 84 | 15 |
| Farxiga | Dapagliflozin Propanediol | 82 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 81 | 17 |
| Baclofen | Baclofen | 78 | 18 |
| Fluticasone Propionate | Fluticasone Propionate | 76 | 21 |
| Memantine Hcl | Memantine Hcl | 75 | suppressed |
| Torsemide | Torsemide | 75 | 17 |
| Allopurinol | Allopurinol | 74 | 17 |
| Tresiba Flextouch U-100 | Insulin Degludec | 74 | 11 |
| Celecoxib | Celecoxib | 71 | 18 |
| Famotidine | Famotidine | 71 | 12 |
| Pravastatin Sodium | Pravastatin Sodium | 70 | 16 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 64 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 63 | 13 |
| Ozempic | Semaglutide | 58 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 58 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 57 | 17 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 55 | 38 |
| Estradiol | Estradiol | 49 | 12 |
| Benazepril Hcl | Benazepril Hcl | 44 | 11 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 44 | 13 |
| Jardiance | Empagliflozin | 44 | suppressed |
| Carvedilol | Carvedilol | 42 | 12 |
| Clonazepam | Clonazepam | 42 | suppressed |
| Atenolol | Atenolol | 41 | 11 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 41 | suppressed |
| Spironolactone | Spironolactone | 41 | 14 |
| Lamotrigine | Lamotrigine | 40 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 40 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 38 | 19 |
| Azelastine Hcl | Azelastine Hcl | 38 | 20 |
| Glipizide | Glipizide | 38 | suppressed |
| Ramipril | Ramipril | 38 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 38 | 11 |
| Amiodarone Hcl | Amiodarone Hcl | 35 | 12 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 35 | 11 |
| Digoxin | Digoxin | 34 | suppressed |
| Dutasteride | Dutasteride | 34 | suppressed |
| Levetiracetam | Levetiracetam | 33 | suppressed |
| Linzess | Linaclotide | 31 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 30 | suppressed |
| Rytary | Carbidopa/Levodopa | 30 | suppressed |
| Nabumetone | Nabumetone | 29 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 29 | suppressed |
| Acarbose | Acarbose | 28 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 28 | 21 |
| Nystatin | Nystatin | 28 | 16 |
| Tresiba Flextouch U-200 | Insulin Degludec | 28 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 26 | 11 |
| Quetiapine Fumarate | Quetiapine Fumarate | 26 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 25 | suppressed |
| Ezetimibe | Ezetimibe | 25 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 25 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 25 | suppressed |
| Bumetanide | Bumetanide | 23 | suppressed |
| Lorazepam | Lorazepam | 23 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 23 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 21 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 21 | suppressed |
| Januvia | Sitagliptin Phosphate | 21 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 21 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 20 | 13 |
| Dapagliflozin | Dapagliflozin Propanediol | 20 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 20 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 20 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 20 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 20 | suppressed |
| Cephalexin | Cephalexin | 19 | 13 |
| Synthroid | Levothyroxine Sodium | 19 | suppressed |
| Tramadol Hcl Er | Tramadol Hcl | 19 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 18 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 18 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 18 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 18 | suppressed |
| Pregabalin | Pregabalin | 18 | suppressed |
| Fluconazole | Fluconazole | 17 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 17 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 17 | suppressed |
| Lidocaine | Lidocaine | 17 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 17 | 12 |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 16 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 16 | suppressed |
| Fluvastatin Sodium | Fluvastatin Sodium | 16 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 16 | suppressed |
| Latanoprost | Latanoprost | 16 | suppressed |
| Lovastatin | Lovastatin | 16 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 16 | suppressed |
| Ondansetron Odt | Ondansetron | 16 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 16 | suppressed |
| Aripiprazole | Aripiprazole | 15 | suppressed |
| Cefdinir | Cefdinir | 15 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 15 | suppressed |
| Norethindrone-E.Estradiol-Iron | Norethindrone-E.Estradiol-Iron | 15 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 15 | 13 |
| Oxybutynin Chloride | Oxybutynin Chloride | 15 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 15 | suppressed |
| Verapamil Er | Verapamil Hcl | 15 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 14 | suppressed |
| Dofetilide | Dofetilide | 14 | suppressed |
| Ibuprofen | Ibuprofen | 14 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 14 | suppressed |
| Peg 3350-Electrolyte | Sodium Chloride/Nahco3/Kcl/Peg | 14 | 14 |
| Risperidone | Risperidone | 14 | suppressed |
| Amoxicillin | Amoxicillin | 13 | 13 |
| Bupropion Xl | Bupropion Hcl | 13 | suppressed |
| Diltiazem 24hr Er (Xr) | Diltiazem Hcl | 13 | suppressed |
| Premarin | Estrogens, Conjugated | 13 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 13 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Diazepam | Diazepam | 12 | suppressed |
| Fenofibrate | Fenofibrate | 12 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 12 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Levemir Flexpen | Insulin Detemir | 12 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 12 | suppressed |
| Mesalamine | Mesalamine | 12 | suppressed |
| Nifedipine Er | Nifedipine | 12 | suppressed |
| Sucralfate | Sucralfate | 12 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 12 | suppressed |
| Trulicity | Dulaglutide | 12 | suppressed |
| Vraylar | Cariprazine Hcl | 12 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 12 | suppressed |
| Acyclovir | Acyclovir | 11 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 11 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 11 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 11 | suppressed |
| Levofloxacin | Levofloxacin | 11 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 11 | suppressed |
| Nitroglycerin | Nitroglycerin | 11 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $98.54 · 5 records | Novartis Pharmaceuticals Corporation | CAPVAXIVE, GARDASIL 9, LEQVIO, Ozempic, REXULTI | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Novo Nordisk Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error